ClinicalTrials.gg
RecruitingNCT06528158EMA-FRaMUpdated Nov 5, 2026

Speech Groups for Children Living With a Sibling Who Suffers From Anorexia Nervosa

An observational study in Anorexia Nervosa, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University Hospital, Toulouse · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
24
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Anorexia Nervosa with a site in France — 16 open to participants now, 21 under way, 1 of them phase 3. Anorexia Nervosa · France.

Planned enrollment
23rd of 31
24 · median 87
Started
2025
with 2 others
Observational
31 of 79
7 open now
Primary completion
2027-08
later than 11 of 20 live
Registered
73rd of 79
by date

Among the 79 studies in Anorexia Nervosa with a site in France, this one is the 23rd largest by planned enrollment of the 31 observational ones that give a count, is one of 3 that started in 2025, is one of 31 observational ones, reaches primary completion later than 11 of the 20 other live ones, and was the 73rd registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

16 of the 79 studies in Anorexia Nervosa with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Anorexia Nervosa with a site in France, or all of them as a file.
02

Study summary

Anorexia nervosa (AN) is a complex mental disease with a huge impact on the patient's siblings life and well-being. Based on literature, group interventions for siblings of children suffering from a chronic disease could provide an effective support. A few have been studied, and even fewer exist for siblings of children with AN.

Read the detailed description

AN has a significant impact on nuclear family (parents and siblings). An emerging literature highlights the need for a particular attention to siblings. Despite this evidence, research and clinical applications still lack in this area. Indeed, most of health services in AN offer support for patients, family, parents, but only few specific support for siblings, although positive outcomes of sibling group interventions were reported in other somatic and psychic disabilities.

Noting the gap between the need and the lack of specific support, the study hypothesis is that the poor diffusion of these interventions in AN might result from a low acceptability. The study propose to explore acceptability to adapt and improve group intervention for siblings of children and teenagers receiving care for anorexia nervosa.

The study is a mixed-method pilot study assessing the acceptability of a group intervention by including a maximum of 24 siblings of children suffering from AN, aged from 8 to 18, across three group sessions, each consisting of 4 meetings. All participants will be invited to fulfill two different auto-questionnaires about their quality of life (before and after group session) and the intervention's acceptability (after group session).

Quantitative data will be complemented with qualitative data, collected from individual semi-structured interviews with a targeted sampling among group participants.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

Keywords

  • siblings
  • groups
  • children
  • teenagers
  • acceptability
04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Maximum 24 participants will overall be included to attend group sessions. Around 15 participants will be invited to an individual interview after group sessions.

Eligibility criteria

  • inclusion criteria : Sibling presenting a DSM (Diagnostic and Statistical Manual)-5 of Mental Disorders diagnosis of AN, and engaged in inpatient or outpatient healthcare
  • exclusion criteria :

    • (1) Opposition from the participant and/or from their legal representatives.
    • (2) Non-fluent French speaker
    • (3) Clinical presentation not compatible with the group sessions
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No

Interventions

  • Othersibling group

    The group will be based on a systemic model and led by two child psychiatrists trained in family and multi-family therapy, who will not subsequently be involved in the data analysis. It will consist of 4 sessions of 1h30, spread over a period of 2 months, with a maximum of 8 participants per session. The first 3 sessions will be spaced 15 days apart, and the last session will take place 3 weeks apart from the third session. The characteristics of the group (frequency, duration, number of sessions and participants) were built on data from the literature as well as on clinical feedback from a first pilot group conducted in January and February 2024 on the Toulouse pediatric unit by the two therapists who will lead the groups during the study.

06

What researchers measure

Primary outcomes

  1. Group ACCEPTABILITY

    assess the clinical setting " sibling group "'s acceptability among siblings of teenagers engaged in health care for AN. This will be assessed through the acceptability scale Abbreviated Acceptability Rating Profile (AARP) after attending group sessions. In the questionnaire, there are 8 questions. For each, a scale of 1 to 6, with 1 being "not agreeing at all with the question" and 6 being "completely agree". Maximum score = 48 the higher the score, the better the acceptability of the group is felt by participants.

    Time frame: after attending group sessions, maximum 3 months after baseline

Secondary outcomes

  1. Impact of the groups on quality of life

    THE PEDIATRIC QUALITY OF LIFE INVENTORY VERSION 4 (PEDSQLTM4.0) (MODULE GENERIC CORE SCALE) The PedsQL is a modular instrument for measuring health-related quality of life (HRQOL) in children and adolescents ages 2 to 18. The PedsQL 4.0 Generic Core Scales are multidimensional child self-report and parent proxy-report scales developed as the generic core measure to be integrated with the PedsQL Disease-Specific Modules. The PedsQL 4.0 Generic Core Scales consist of 23 items A 5-point response scale is used across the child self-report (for ages 8 to 18) and parent proxy-report (0 = never a problem; 1 = almost never a problem; 2 = sometimes a problem; 3 = often a problem; 4 = almost always a problem). A 3-point scale is us

    Time frame: baseline

  2. impact of the groups on quality of life

    THE PEDIATRIC QUALITY OF LIFE INVENTORY VERSION 4 (PEDSQLTM4.0) (MODULE GENERIC CORE SCALE) The PedsQL is a modular instrument for measuring health-related quality of life (HRQOL) in children and adolescents ages 2 to 18. The PedsQL 4.0 Generic Core Scales are multidimensional child self-report and parent proxy-report scales developed as the generic core measure to be integrated with the PedsQL Disease-Specific Modules. The PedsQL 4.0 Generic Core Scales consist of 23 items A 5-point response scale is used across the child self-report (for ages 8 to 18) and parent proxy-report (0 = never a problem; 1 = almost never a problem; 2 = sometimes a problem; 3 = often a problem; 4 = almost always a problem). A 3-point scale is us

    Time frame: after attending group sessions, maximum 3 months after baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2027, 31 months after the start.

Of 56 non-industry observational studies under Anorexia Nervosa, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 31 months is below that.

Counting every sponsor, half of 56 studies reached it within 38 months; a quarter within 16 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Jan 2, 2025
Primary completionEst.
Aug 2, 2027was Aug 2026
CompletionEst.
Aug 2, 2027was Aug 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2, 2026→Aug 2, 2027
Nov 5, 2026
Study completion
Aug 2, 2026→Aug 2, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Aug 2, 2026→Aug 2, 2027
    Study completion Aug 2, 2026→Aug 2, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06528158
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Jan 2, 2025
Primary completion
Aug 2, 2027 (estimated)
Completion
Aug 2, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Antoine STOCKER, MD
Contact
stocker.a@chu-toulouse.fr
05 61 77 22 33
Antoine STOCKER, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion